ArticleThe Journal of experimental medicine2000
Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides.
Article in The Journal of experimental medicine, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Hijacking Host Immunity by the Human T-Cell Leukemia Virus Type-1: Implications for Therapeutic and Preventive Vaccines.Viruses · 2022Review
- Short-term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax-specific CTL response in adult T-cell leukemia patients.Cancer science · 2021Article
- Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- p30 protein: a critical regulator of HTLV-1 viral latency and host immunity.Retrovirology · 2019Review
- Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors.Retrovirology · 2019Review
- Article
- Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL.Retrovirology · 2019Review
- The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30Virology · 2018Article
- The coordination of unprotonated peptide tertiary structure as a metric of pMHC-TCR functional avidity.Data in brief · 2015Article
- Discovery and characterization of auxiliary proteins encoded by type 3 simian T-cell lymphotropic viruses.Journal of virology · 2015Article
- Atomic Coordination Reflects Peptide Immunogenicity.Frontiers in molecular biosciences · 2015Article
- Quantum chemical calculations predict biological function: the case of T cell receptor interaction with a peptide/MHC class I.Frontiers in chemistry · 2015Article
- The need to accessorize: molecular roles of HTLV-1 p30 and HTLV-2 p28 accessory proteins in the viral life cycle.Frontiers in microbiology · 2013Review
- Human T-lymphotropic virus type 1 non-structural proteins: Requirements for latent infection.Cancer science · 2013Review
- Overview on HTLV-1 p12, p8, p30, p13: accomplices in persistent infection and viral pathogenesis.Frontiers in microbiology · 2012Article
- The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases.Frontiers in microbiology · 2012Article
- Review
- Human T-lymphotropic virus type 1 p30 interacts with REGgamma and modulates ATM (ataxia telangiectasia mutated) to promote cell survival.The Journal of biological chemistry · 2011Article
- HTLV-I p30: a versatile protein modulating virus replication and pathogenesis.Molecular aspects of medicine · 2010Article
- Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins.Molecular aspects of medicine · 2010Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human T cell leukemia virus type I (HTLV-I) is a persistent virus that causes adult T cell leukemia and tropical spastic paraparesis/HTLV-I-associated myelopathy. Studies on rabbits have shown that viral proteins encoded by the open reading frames pX-I and pX-II are required for the establishment of the persistent infection. To examine the in vivo production of these proteins in humans, we have investigated whether cytotoxic T lymphocytes isolated from HTLV-I-infected individuals recognized pX-I and pX-II peptides. CD8(+) T lymphocytes to pX-I and pX-II peptides were detected in HTLV-I-infected individuals, whatever their clinical status, and even in the absence of any antigenic restimulation. These findings indicate that the HTLV-I pX-I and pX-II proteins are chronically synthesized in vivo, and are targets of the natural immune response to the virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.